Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Palace setting offers touch of magic to Olympic equestrian events
Recommended
What are the best neighborhoods in Raleigh, NC
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
10.00
-0.19 (-1.86%)
Streaming Delayed Price
Updated: 10:34 AM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 17, 2023
Via
Benzinga
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
July 17, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
July 17, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for Travere Therapeutics
June 07, 2023
Via
Benzinga
11 Analysts Have This to Say About Travere Therapeutics
May 22, 2023
Via
Benzinga
Recap: Travere Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
Earnings Outlook For Travere Therapeutics
May 03, 2023
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
April 17, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
July 05, 2023
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.
Via
Investor's Business Daily
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 08, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
Travere Therapeutics to Present at Upcoming Investor Conferences
June 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
May 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks With Blockbuster Potential
May 24, 2023
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
May 22, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports First Quarter 2023 Financial Results
May 04, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 02, 2023
Via
Benzinga
Chegg, Community Health Systems, Metropolitan Bank And Other Big Stocks Moving Lower On Tuesday
May 02, 2023
U.S. stocks traded lower, with the Dow Jones losing around 477 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
May 02, 2023
From
The Schall Law Firm
Via
Business Wire
Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test
May 02, 2023
Travere was testing a treatment for FSGS, a condition that causes kidney scarring.
Via
Investor's Business Daily
Travere Therapeutics' Rare Kidney Disease Drug Disappoints In Phase 3 Study, Analyst Says Efficacy Trends Suggest Potential Path Forward
May 02, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) announced
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 02, 2023
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
May 01, 2023
From
The Schall Law Firm
Via
Business Wire
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
May 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report First Quarter 2023 Financial Results
April 26, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch
April 03, 2023
Via
Benzinga
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
April 01, 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.